A Phase 1, First-in-Human, Randomized, Observer-blind, Controlled, Dose-ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Self-Amplifying mRNA Seasonal Influenza Vaccine (ARCT-2138), When Administered to Healthy Adults
Arcturus Therapeutics, Inc. is advancing ARCT-2138, a self-amplifying mRNA vaccine for seasonal influenza, through a Phase 1 clinical trial. This innovative approach leverages mRNA technology, which has gained significant traction due to its success in COVID-19 vaccines. The market for seasonal influenza vaccines is substantial, with ongoing demand for improved efficacy and safety profiles. The competitive landscape includes established players like Seqirus and Sanofi, which may pose challenges. Successful trial outcomes could position Arcturus favorably for partnerships or acquisitions, enhancing its market presence in the vaccine sector.
Indication: Influenza, Human
Modality: protein therapy
Target: Self-amplifying mRNA platform targeting seasonal influenza virus antigens.
Sponsor: Arcturus Therapeutics, Inc.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 15, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Self-amplifying mRNA platform targeting seasonal influenza virus antigens.
View original source fields
Condition raw: Influenza, Human
Condition normalized: Influenza, Human
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Self-amplifying mRNA platform targeting seasonal influenza virus antigens.
Target normalized: Self-amplifying mRNA platform targeting seasonal influenza virus antigens.